Quest Diagnostics’ Haystack MRD® Test Earns FDA Breakthrough Device Designation for Early-Stage Colorectal Cancer
Quest Diagnostics (NYSE: DGX), a prominent leader in diagnostic information services, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Haystack MRD® test. This innovative test is designed to identify MRD-positive patients with…